Core 4: Animal Breeding (UAB) and Exposure Core (MRIGLOBAL)
核心 4:动物育种 (UAB) 和暴露核心 (MRIGLOBAL)
基本信息
- 批准号:10249112
- 负责人:
- 金额:$ 57.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntidotesArsenicalsAttenuatedBackBar CodesBody FluidsCenters of Research ExcellenceChemical AgentsChemical Warfare AgentsChemicalsCutaneousDataData CollectionEvaluationExposure toFlowchartsFundingGrantHousingIn VitroKidneyLaboratoriesLiquid substanceLungModelingMolecular TargetNitrogenOxidesProceduresProtocols documentationRunningSafetySamplingScheduleScientistServicesShipsSkinTechniquesTemperatureTestingTimeTissue HarvestingTissuesToxic effectVisitWorkanimal breedinganimal colonybiobankchemical threatdrug developmentdrug discoveryexperienceexperimental studyhealingin vivonoveloperationprogramsprototyperenal damagescreeningskin damageskin lesionsuccesstoxic industrial chemical
项目摘要
The major objectives of the Animal and Exposure Core-4 of the UAB Research Center of
Excellence in Arsenicals are to support all scientific Projects and Drug Discovery and
Development Core-3, as the success of the studies proposed within this Center application
depend on the availability of sufficient animals in a timely manner, as well as the timely
coordination with MRIGlobal for animal exposure to arsenicals. MRIGlobal has more than 60
years of corporate experience in management and operations of chemical agent facilities and
associated projects. We bring to CACT-funded programs, proficiencies in small and large animal
chemical agent models, test and evaluation, safe handling of chemical warfare agent (CWA)
compounds, compounds with extreme toxicity, toxic industrial chemicals (TIC), and emerging
chemical threats. Core-4 will generate a colony of animals of the desired size by assessing the
requirement of each Project in the beginning of each year. Animals will be transported to
MRIGlobal on a predefined time schedule. Once the animals have been exposed to arsenicals
and their initial gross data pertaining to skin damage recorded, the animals will be euthanized by
the staff at MRIGlobal and the harvested tissues and body fluids will be transported back to UAB.
In addition, MRIGlobal will synthesize and store the arsenicals used for these animal studies for
which they have facilities which approved by appropriate agencies. Core-4 will establish a
biorepository on the UAB campus in which to store the returned tissue and body fluid samples as
well as other samples generated directly by the Projects. Samples will be barcoded and banked
in our laboratory. In addition, Core-4 will conduct the in vivo screening of agents that are
synthesized by Drug Discovery and Development Core-3 and found to be highly effective in
attenuating molecular targets in vitro. Accordingly, three specific aims of this core include: 1: To
breed and ship animals for arsenicals exposure at MRIGlobal under approved animal protocols
of UAB and MRIGlobal; 2: Coordinate with MRIGlobal for animal exposure to arsenicals, initial
gross skin data collection, and return shipment to UAB of samples or healed animals for proper
banking and distribution or further toxicity assessment, respectively; and 3: To perform in vivo
screening of novel agents developed in Drug Discovery and Development Core-3.
UAB研究中心的动物和暴露核心-4的主要目标是
卓越的砷是支持所有的科学项目和药物发现,
开发核心-3,作为本中心申请中提出的研究的成功
这取决于及时提供足够的动物,以及及时
与MRIGlobal协调动物接触砷的情况。MRIGlobal拥有60多个
多年的化学剂设施管理和运营企业经验,
相关项目。我们为CACT资助的项目带来了小型和大型动物的专业知识,
化学战剂模型,试验与评估,化学战剂安全处置
化合物,具有极端毒性的化合物,有毒工业化学品(TIC),以及新兴的
化学威胁。核心-4将通过评估动物的生长情况来产生所需大小的动物群体。
每年年初,每个项目的需求。动物将被运送到
在预定义的时间表上执行MRI Global。一旦动物接触到砷剂
记录与皮肤损伤相关的初始大体数据,动物将通过以下方式实施安乐死:
MRIGlobal的工作人员以及采集的组织和体液将被运回UAB。
此外,MRIGlobal将合成和储存用于这些动物研究的砷剂,
他们有适当机构批准的设施。核心-4将建立一个
UAB校园内的生物储存库,用于储存返回的组织和体液样本,
以及由项目直接生成的其他样本。将对样本进行条形码标记并储存
在我们的实验室里。此外,Core-4将进行体内药物筛选,
由药物发现和开发核心-3合成,并发现在
在体外减弱分子靶点。因此,该核心的三个具体目标包括:
根据批准的动物方案,在MRIGlobal繁殖和运输动物进行砷暴露
2:就动物暴露于砷剂问题与MRIGlobal协调,初始
收集皮肤大体数据,并将样本或治愈的动物运回UAB,以进行适当的
分别储存和分发或进一步毒性评估;和3:在体内进行
筛选药物发现和开发核心3中开发的新药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Athar其他文献
Mohammad Athar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Athar', 18)}}的其他基金
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10259711 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10023318 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10700044 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
砷皮肤损伤新型分子靶点药物的优化
- 批准号:
10886403 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Project 1: Novel Pharmacological Inhibitors of Chemical Vesicants-mediated Cutaneous Injury
项目1:化学糜烂介导的皮肤损伤的新型药理抑制剂
- 批准号:
10249113 - 财政年份:2018
- 资助金额:
$ 57.52万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
9767149 - 财政年份:2018
- 资助金额:
$ 57.52万 - 项目类别:
UAB Research Center of Excellence in Arsenicals
阿拉巴马大学砷化合物卓越研究中心
- 批准号:
10249107 - 财政年份:2018
- 资助金额:
$ 57.52万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10263928 - 财政年份:2017
- 资助金额:
$ 57.52万 - 项目类别:
Core 3: Rexinoid Screening and Animal Core
核心 3:Rexinoid 筛选和动物核心
- 批准号:
10493962 - 财政年份:2017
- 资助金额:
$ 57.52万 - 项目类别:
相似海外基金
Novel oxime antidotes for an organophosphate insecticide requiring bioactivation
用于需要生物活化的有机磷杀虫剂的新型肟解毒剂
- 批准号:
10629574 - 财政年份:2023
- 资助金额:
$ 57.52万 - 项目类别:
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 57.52万 - 项目类别:
Dual cavity baskets as nano antidotes for overdose with fentanyl and its derivatives
双腔篮作为芬太尼及其衍生物过量服用的纳米解毒剂
- 批准号:
10369058 - 财政年份:2021
- 资助金额:
$ 57.52万 - 项目类别:
Antidotes against HCI-induced chronic lung injury
针对 HCI 引起的慢性肺损伤的解毒剂
- 批准号:
10015581 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Antidotes against HCI-induced chronic lung injury
针对 HCI 引起的慢性肺损伤的解毒剂
- 批准号:
10241958 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning
用于治疗一氧化碳中毒的血红蛋白解毒剂
- 批准号:
10282997 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Antidotes against HCI-induced chronic lung injury
针对 HCI 引起的慢性肺损伤的解毒剂
- 批准号:
10471329 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning
用于治疗一氧化碳中毒的血红蛋白解毒剂
- 批准号:
10296690 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别:
Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning
用于治疗一氧化碳中毒的血红蛋白解毒剂
- 批准号:
9908358 - 财政年份:2020
- 资助金额:
$ 57.52万 - 项目类别: